Progress on Launch of Biomarker Test in USA

AI SummaryClose X

Cizzle Biotechnology Holdings Plc has provided an update on its CIZ1B biomarker test for early lung cancer detection, with its North American partner Cizzle Bio Inc nearing CLIA accreditation in the USA, expected in Q2 2026. The company has received US$590,000 of guaranteed advance payments and has agreed to a revised schedule ensuring the remaining US$1.81m of initial payments are received by the end of 2026. Furthermore, a new agreement includes a minimum of US$3.5m in guaranteed royalty payments over the seven years following the current agreement's extension in 2031, bringing the total confirmed minimum payments to US$5.9m.

Disclaimer*

UK 100

Latest directors dealings